An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.

NCT06519344 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

B Cell Malignancies

Interventions

BIOLOGICAL: anti-CD20/CD30-CAR-T Cells

Sponsor

Shanghai Tongji Hospital, Tongji University School of Medicine